Average cost per year*
Average cost per beneficiary*
This medication is a man-made antibody (IgG1) used to treat various types of cancer. This drug works by blocking a certain protein (vascular endothelial growth factor-VEGF) thereby decreasing the blood supply to the tumor and slowing tumor growth. This monograph is about the following bevacizumab products: bevacizumab, bevacizumab-awwb, and bevacizumab-bvzr. NOTE: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
*Origin of the terms and chart data used within this page: https://data.cms.gov/
Yes, Avastin is covered by Medicare.
In 2021, the average cost per dose of Avastin was $211.01.
The average dose of Avastin received per year is 106,738 units
596 Medicare beneficiaries received Avastin in 2021, which was a -0.14% from 2020
There were 3,153 claims made by Medicare beneficiaries, which is a -0.13% from 2020
The average spending amount per claim in 2021 was $6,077.56
The average Medicare spending per beneficiary amount for Avastin was $32,151.91
Genentech, Inc. received $19,162,538.59
The total amount spent on Avastin by Medicare is $19,162,538.59
Short Term Medical Insurance
Limited Fixed Indemnity Plans